Insulin list prices have escalated dramatically during the past 5-10 years. This is due to only three manufacturers controlling the market, the lack of alternative insulins, and manufacturer abuse of patent extensions. PBMs drive competition using drug formularies and rebates.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: The latest NHE survey shows that the retail prescription drug net price index declined
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. RX DRUG AFFORDABILITY BOARDS: NO PRICE SETTING & COME ONE, COME
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WISCONSIN EMPLOYERS ON WHITE BAGGING… Recently, we introduced you to the
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Energy and Commerce Committee’s inclusion of full repeal of the rebate rule in the committee’s legislative recommendations for its budget reconciliation bill
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden administration’s plan for high drug prices: “While we review the recently released Comprehensive Plan for Addressing High Drug Prices report,
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WHAT IS WHITE BAGGING… There’s a lot of jargon in
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data by the Centers for Medicare & Medicaid Services (CMS) on prescription drug costs, showing that pharmacy benefit managers (PBMs) reduce
©2024 PCMA. All Rights Reserved.
